The fibrotic diseases treatment market addresses a growing class of chronic, progressive conditions characterized by excessive scar tissue formation in organs such as the lungs, liver, heart, and kidneys. These disorders—including idiopathic pulmonary fibrosis, liver fibrosis, cardiac fibrosis, and renal fibrosis—lead to organ dysfunction, reduced quality of life, and significant...